MX2024012083A - Formulaciones intraorales alcalinas - Google Patents

Formulaciones intraorales alcalinas

Info

Publication number
MX2024012083A
MX2024012083A MX2024012083A MX2024012083A MX2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A MX 2024012083 A MX2024012083 A MX 2024012083A
Authority
MX
Mexico
Prior art keywords
nicotine
intraoral
formulations
alkaline
chemically bonded
Prior art date
Application number
MX2024012083A
Other languages
English (en)
Spanish (es)
Inventor
Håkan Engqvist
Jesper Lööf
Original Assignee
Emplicure Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2204804.5A external-priority patent/GB2613211B/en
Priority claimed from GBGB2208807.4A external-priority patent/GB202208807D0/en
Application filed by Emplicure Ab Publ filed Critical Emplicure Ab Publ
Publication of MX2024012083A publication Critical patent/MX2024012083A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
MX2024012083A 2022-04-01 2024-09-30 Formulaciones intraorales alcalinas MX2024012083A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2204804.5A GB2613211B (en) 2022-04-01 2022-04-01 Alkaline oral formulations
GBGB2208807.4A GB202208807D0 (en) 2022-06-15 2022-06-15 Alkaline intraoral formulations
PCT/EP2023/058713 WO2023187224A1 (en) 2022-04-01 2023-04-03 Alkaline intraoral formulations

Publications (1)

Publication Number Publication Date
MX2024012083A true MX2024012083A (es) 2025-01-09

Family

ID=86096079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012083A MX2024012083A (es) 2022-04-01 2024-09-30 Formulaciones intraorales alcalinas

Country Status (7)

Country Link
US (1) US20250228770A1 (https=)
EP (1) EP4504146B1 (https=)
JP (1) JP2025513763A (https=)
CN (1) CN119136784A (https=)
CA (1) CA3246977A1 (https=)
MX (1) MX2024012083A (https=)
WO (1) WO2023187224A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9848634B2 (en) * 2009-06-30 2017-12-26 Philip Morris Products S.A. Smokeless tobacco product
CN101966165B (zh) * 2009-07-14 2012-06-13 无锡健而乐医药科技有限公司 口腔吸收固体泡腾制剂
SE535587C2 (sv) 2011-03-29 2012-10-02 Chill Of Sweden Ab Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse
CN103284318B (zh) * 2013-06-20 2015-03-11 中国烟草总公司山东省公司 一种舌下烟及其制备方法
WO2015193379A1 (en) * 2014-06-18 2015-12-23 Swedish Match North Europe Ab A tobacco or non-tobacco product comprising magnesium carbonate
CN107259635A (zh) * 2017-06-16 2017-10-20 云南中烟工业有限责任公司 一种烟碱复合盐含化片及其制备方法
GB201714412D0 (en) * 2017-09-07 2017-10-25 Emplicure Ab Evaporation devices containing plant material
WO2019110073A1 (en) 2017-12-08 2019-06-13 Fertin Pharma A/S Solid oral nicotine formulation
CA3085065C (en) * 2017-12-08 2023-12-05 Fertin Pharma A/S Formulations providing high nicotine concentrations
JP2022519542A (ja) * 2019-02-01 2022-03-24 スウィーディッシュ・マッチ・ノース・ヨーロップ・アーベー pH調整剤を含む経口用ニコチン製品
US20210169123A1 (en) * 2019-12-09 2021-06-10 Nicoventures Trading Limited Pouched products with enhanced flavor stability
GB202105305D0 (en) * 2021-04-14 2021-05-26 Zanoprima Lifesciences Ltd Supported nicotine composition

Also Published As

Publication number Publication date
WO2023187224A1 (en) 2023-10-05
US20250228770A1 (en) 2025-07-17
EP4504146A1 (en) 2025-02-12
JP2025513763A (ja) 2025-04-30
EP4504146B1 (en) 2025-12-17
CN119136784A (zh) 2024-12-13
CA3246977A1 (en) 2023-10-05
EP4504146C0 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
ECSP045517A (es) Procedimiento para dejar de fumar
ES2174073T3 (es) Forma farmaceutica solida para uso oral.
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR113901A1 (es) Uso tópico y entrega de microorganismos oxidantes de amoniaco
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ES2089260T3 (es) Composicion topica que contiene lisinato de cetoprofeno.
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
ES2194328T3 (es) Sistema de higiene femenina y kit que usa un dispositivo interlabial absorbente.
ES2106782T3 (es) Uso de una composicion de fumado.
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
MX9702415A (es) Extractos de cocoa antineoplastica y metodos para elaborar y usar los mismos.
CY1107649T1 (el) Συνδυασμος ο οποιος περιεχει ενα αντιφολικο αλας και παραγοντα ελαττωσης μεθυλομηλονικου οξεος
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
CO2024012870A2 (es) Tratamiento de neurofibromas cutáneos con mirdametinib
AR047986A1 (es) Composiciones de pelicula
CL2012000169A1 (es) Composicion farmaceutioca de jarabe que comprende omeprazol o una sal del mismo, un agente solubilizante, un agente basificante, o un tampon, un edulcorente, un aromatizante y un antooxidante; metodo de preparacion; kit que comprende a la formulacion.
MX2024012083A (es) Formulaciones intraorales alcalinas
ECSP034617A (es) Kit de repinotan
MX2021011420A (es) Lamina hemostatica portadora de trombina.
MX2024012081A (es) Formulaciones de nicotina
DE50109650D1 (de) Topische behandlung bei der mastalgie
AR000504A1 (es) Procedimiento para la producción de una solución acuosa biocida de acción prolongada basada en ionesperacéticos
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
AR027287A1 (es) Gonadotrofina